LEGEND BIOTECH CORPORA

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 сен 2024 15:35:00 Источник Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

10 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

02 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire